MedicalResearch.com - Latest news, interviews, and insights into medical research, health and wellness, fitness and addiction.
Legal-Malpractice, Occupational Health, Pulmonary Disease / 29.05.2025

The American Lung Organization says 2.3 million US workers are exposed to silica at work. Most of the workers come from the construction industry. Exposure to silica at work mostly happens in the construction industry. Silicosis can develop from silica exposure. The disease is incurable, but its symptoms can be managed through treatments. According to silicosis attorney Christopher J. Canlas, workers who have been exposed to silica dust may get silicosis. Inhaling silica may injure you forever or even kill you. A silicosis attorney can help you check if you have an occupational disease and obtain compensation for your illness. Legal assistance can help secure payments for medical bills, lost wages, and other damages. The support of an experienced lawyer can result in the identification of a liable party for your illness. They will assess whether negligence or regulatory violations played a role in your silicosis diagnosis. They can also help you file claims or lawsuits.  Legal assistance may be necessary after a silicosis diagnosis to protect your rights and future. (more…)
Author Interviews, Boehringer Ingelheim, NEJM, Pulmonary Disease / 15.05.2022

MedicalResearch.com Interview with: Professor Luca Richeldi MD PhD Chair and Head, Division of Pulmonary Medicine Gemelli University Hospital - IRCCS Catholic University of the Sacred Heart Rome MedicalResearch.com:  What is the background for this study?  Would you briefly explain the condition of Idiopathic Pulmonary Fibrosis? Response: As you may know, Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible lung disease with high mortality. IPF is one of the more common forms of progressive fibrosing interstitial lung diseases and its symptoms of IPF include breathlessness during activity, a dry and persistent cough, chest discomfort, fatigue and weakness. IPF is considered a “rare” disease, but it affects more than 3 million people worldwide. Currently, there are two approved antifibrotic drugs that slow, but do not stop, the progression of fibrosis. Therefore, there is a need for additional treatments that can be used alone or with existing antifibrotic therapies. Pre-clinical research indicated that phosphodiesterase 4 (PDE4) inhibition is associated with anti-inflammatory and antifibrotic effects that may be beneficial in patients with idiopathic pulmonary fibrosis. In this Phase 2, double-blind, placebo-controlled trial, we investigated the efficacy and safety of BI 1015550, an oral preferential inhibitor of the PDE4B subtype, in patients with IPF. Patients were randomly assigned in a 2:1 ratio to receive BI 1015550 at a dose of 18 mg twice daily or placebo. (more…)